An Overview on Synthetic and Medicinal Perspectives of [1, 2, 4]Triazolo[1, 5‐a]pyrimidine Scaffold. Issue 9 (10th August 2022)

• Record Type: Journal Article
• Authors: Merugu, Srinivas Reddy; Cherukupalli, Srinivasulu; Karpoormath, Rajshekhar
• Is Part Of: Chemistry & biodiversity. Volume 19:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-08-10
• Subjects: [1, 2, 4]triazolo[1, 5-a]pyrimidine -- synthetic strategies -- anti-infectious agents -- agrochemicals -- anti-cancer agents -- CNS agents -- SAR studies; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Biodiversity -- Periodicals; 572
• DOI: 10.1002/cbdv.202200291
• Languages: English
• ISSNs: 1612-1872

Abstract

Abstract: [1, 2, 4]Triazolo[1, 5‐ a ]pyrimidine is an important heterocyclic scaffold known to have a wide range of pharmacological activities such as anticancer, antimicrobial, anti‐tubercular, CB2 cannabinoid agonists, feticide, and adenosine antagonists. Several clinical trials and marketed drugs such as Trapidil, Essramycin, Pyroxsulam, DSM‐265, Flumetsulam, GNF‐6702, and Cevipabulin indicate the potential of [1, 2, 4]triazolo[1, 5‐ a ]pyrimidine moiety with various functional groups in medicinal chemistry. Herein, we represent a concise report focusing on the synthetic strategies used for diversely substituted [1, 2, 4]triazolo[1, 5‐ a ]pyrimidine analogs and their pharmacological applications. To the best of our knowledge, since 1980, we are the first to write a review on this emerging scaffold, which reveals the synthetic strategies, and pharmacological activities of differently substituted [1, 2, 4]triazolo[1, 5‐ a ]pyrimidine with special emphasis on structure‐activity relationship studies. Abstract :